News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • IQE wins $14 million multi‑year wafer order for AI and data‑centre applications, sending shares higher.
  • Samsung holds early talks on a potential U.S. ADR after SK Hynix's Nasdaq debut, lifting Seoul-listed shares.
  • Report ties policy changes to 223 stalled clean-energy and manufacturing projects worth $82.9 billion and 111,765 jobs at risk.
  • Vossloh trims 2026 revenue and profit targets and issues a profit warning, causing its shares to slide.
  • Hapag‑Lloyd raises full‑year 2026 earnings guidance on stronger freight rates and volumes, pushing shares up.
  • At least 30 killed and 75 injured in a Bangkok pub fire as investigators probe blocked exits and flammable decorations.
  • Ericsson misses Q2 revenue expectations and confirms CEO retirement, prompting a steep share decline.

Latest Articles

Applied Optoelectronics: Betting on the Laser Bottleneck Winner

Applied Optoelectronics: Betting on the Laser Bottleneck Winner

Applied Optoelectronics (AAOI) has become a go-to supplier for optical transceivers and laser diodes as hyperscalers and AI data-center builders accelerate connectivity spending. The stock has already rallied dramatically, but balance-sheet strength, tight short interest and clear demand catalysts make a tactical long attractive from current levels…

AppLovin's Axon Moment: Betting on AI to Supercharge Ad Conversion

AppLovin's Axon Moment: Betting on AI to Supercharge Ad Conversion

AppLovin (APP) is trading like a growth software name with monster profitability. Strong Q1 prints and the roll-out of Axon AI have pushed revenue and margins higher; the market is pricing a premium (P/E ~42, P/S ~27). This trade idea outlines a disciplined long with entry at $497.00, stop at $430.00 and a $650.00 target over a 180 trading-day hori…

Electromed: High-Margin Medical Device Growth with Clear Upside

Electromed: High-Margin Medical Device Growth with Clear Upside

Electromed (ELMD) is a compact medical-specialties company punching above its weight: roughly $72M of implied revenue, double-digit free cash flow margins, zero debt and solid returns on capital. Technicals are constructive and the stock trades below a recent $40 52-week high. We outline a long trade with a $37.00 entry, $33.00 stop and $45.00 targ…

RH: Luxury Furniture at a Discount — Buy the Dip, Respect the Risks

RH: Luxury Furniture at a Discount — Buy the Dip, Respect the Risks

RH (Restoration Hardware) is a high-end furniture and home-lifestyle name trading well below prior highs despite solid free cash flow, expanding international presence, and continued pricing power. At roughly $153, shares offer asymmetric upside to $220 over a multi-month horizon while offering an attractive free cash flow yield; downside is real, …

Memory Price Surge Sparks Structural Supply Crunch, Morgan Stanley Says

Memory Price Surge Sparks Structural Supply Crunch, Morgan Stanley Says

Memory chip prices have spiked more than sixfold in the past year, a shift Morgan Stanley analysts describe as structural. Forecasts cited in the analysts' note project the memory market to expand from roughly $220 billion in 2025 to about $890 billion in 2026, driven primarily by price increases tied to surging demand for AI-focused memory such as…

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Agios Pharmaceuticals presented detailed results from its RISE UP Phase 3 trial of mitapivat, showing statistically significant hemoglobin improvement and clinically meaningful reductions in transfusion burden and sickle cell pain crises among responders. The data reinforces mitapivat's strong anti-hemolytic profile and potential to improve quality…

No Clear Dominant in Quantum Computing, Analysts Say; Pure-Play Firms Hold Modest Slices of a Large Future Market

No Clear Dominant in Quantum Computing, Analysts Say; Pure-Play Firms Hold Modest Slices of a Large Future Market

Analysts at Bernstein conclude that multiple hardware approaches - including superconducting, trapped-ion and neutral-atom systems - all retain competitive advantages, making a single dominant vendor unlikely. Bernstein expects meaningful commercial quantum advantage around 2030, sizes the long-term addressable market at $90 billion to $170 billion…

The Guidance Problem: Why Broadcom Is Vulnerable Despite AI Hype

The Guidance Problem: Why Broadcom Is Vulnerable Despite AI Hype

Broadcom's guidance note that gross profit margins will continue to fall is a clear structural headwind for a stock trading at premium multiples. Fundamentals still look strong, but the market is paying a very high price for near-term margin stability. This trade idea proposes a short-swing (45 trading days) position sized to the risk, with explici…

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals announced encouraging interim six-month data from their Phase 2 trial of setmelanotide in patients with Prader-Willi Syndrome (PWS), demonstrating clinically meaningful reductions in BMI, fat mass, hyperphagia scores, and anxiety measures. These results strengthen the case for advancing setmelanotide, an MC4R agonist, into Ph…

Why a U.S.-Iran Deal Could Tighten, Not Ease, Fed Policy

Why a U.S.-Iran Deal Could Tighten, Not Ease, Fed Policy

Bank of America analysts caution that a prospective U.S.-Iran agreement, while removing a geopolitical premium, could leave crude oil in a price band that increases inflationary pressure just enough to deter Federal Reserve rate cuts and potentially lead to further tightening instead of relief markets recently priced in.

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics reported additional positive results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene-editing therapy for hereditary angioedema (HAE). The treatment demonstrated an 87% reduction in monthly HAE attacks versus placebo and a favorable safety profile. The data were presented at EAACI …

Capital One After the 27% Pullback - A Tactical Long Backed by Discover Synergies and Better Auto Credit Trends

Capital One After the 27% Pullback - A Tactical Long Backed by Discover Synergies and Better Auto Credit Trends

Capital One has retraced roughly 27% from its January highs, trading near $185 and offering an attractive risk-reward for a tactical long. The Discover acquisition and targeted $2.7B of synergies, improving auto loan performance, strong free cash flow, and a modest balance sheet give the company room to reclaim lost ground. I recommend a mid-term s…

From Parking Lots to Pricey Rooms: World Cup Demand Falls Short in New Jersey

From Parking Lots to Pricey Rooms: World Cup Demand Falls Short in New Jersey

Weeks before the 2026 FIFA World Cup kickoff, hotels and motels near MetLife Stadium have raised rates dramatically but are seeing lower-than-expected bookings. Newly renovated properties advertise premium pricing for the July 19 final while occupancy for earlier matches remains subdued, industry data and hotel staff say. Analysts point to high tic…

Bernstein: Data center growth may not translate into a copper boom

Bernstein: Data center growth may not translate into a copper boom

Bernstein argues that while global data center capacity is set to expand sharply toward 200 GW by 2030, technological shifts and alternative power solutions will limit incremental copper consumption from these facilities. The research house sees near-term annual copper use from data centers stuck at roughly 400,000-500,000 tonnes before declining i…

Progressive: Buy the Growth Story as Underwriting Margins Normalize

Progressive: Buy the Growth Story as Underwriting Margins Normalize

Progressive has engineered industry-leading premium growth and underwriting results. With a market cap near $119B, a P/E around 10x and strong free cash flow, the stock looks actionable on a mid-term rebound. Expect underwriting margins to normalize from cyclical highs, but continued share gains, telematics advantages, and investment income should …